Industry news that matters to you.  Learn more

Archives for November 2012

Novel Cardiac Biomarker Predicts Progression of Heart Failure in Chronic HIV-Infected Patients

Critical Diagnostics, makers of the Presage® ST2 Assay, announced recently that during a presentation at the American Heart Association Scientific Sessions in Los Angeles, the results of a study demonstrated that elevated levels of the biomarker ST2 in HIV patients was strongly indicative of the development of heart failure and mortality.

A Simpler Way to Predict Heart Failure

The most widely used models for predicting heart failure rely on a complex combination of lifestyle, demographic, and cardiovascular risk factor information.

Early Economic Evaluation Highlights the Potential Benefits of Biomarker-Directed Care in Breast Cancer and Renal Cell Carcinoma

GE Healthcare today announced results of three health economic models to estimate the potential cost offsets to the healthcare system of biomarker testing in patients with early breast cancer, metastatic breast cancer and renal cell carcinoma to guide therapy selection. These studies were presented at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 15th European Congress in Berlin, Germany.

Caris Life Sciences Selects Illumina’s MiSeq® System to Enable Next-Generation Sequencing as Part of its Molecular Profiling Service

Illumina, Inc. (NASDAQ:ILMN) announced last week that Caris Life Sciences has selected its MiSeq sequencing system to support Caris’ evidence-based molecular profiling service. The MiSeq system will be deployed to enable rapid, simultaneous analysis of multiple genes from formalin-fixed, paraffin-embedded (FFPE) tumor tissues using Illumina’s amplicon-based assay.

COLTHERES Consortium Identifies Molecular Signatures Leading to Personalized Therapies

COLTHERES (the Colon Therapy Research Consortium), a collaboration of EU-based clinical centers and translational researchers, has revealed in its first interim report key results that will enable a more personalized and effective approach to be taken in treatment of colon cancer using two novel drugs; the EGFR inhibitor Cetuximab and the BRaf inhibitor Vemurafinib.